Dreher - Figure 41

Summary II

NIV is the primary treatment option for patients with acute hypercapnic respiratory failure due to COPD. However, readmission rate and one-year mortality is a very high in patients with acute hypercapnic COPD exacerbation. The HOT-HMV trial assessed long-term NIV after acute respiratory failure in patients with acute-on-chronic (as opposed to acute) respiratory failure,[20] and the results from HOT-HMV are presented and discussed elsewhere in this multimedia publication.

Dreher M. Chest 2017:00.

References

[20]

Murphy P, Arbane G, Bourke S, et al. LATE-BREAKING ABSTRACT: Improving admission free survival with home mechanical ventilation (HMV) and home oxygen therapy (HOT) following life threatening COPD exacerbations: HoT-HMV UK Trial NCT00990132. In: ERS International Congress 2016 abstracts. Eur Respir J. 2016;48(suppl 60):OA3527. doi: 10.1183/13993003.congress-2016.OA3527.